Drugs for Cervix Uteri Carcinoma in Situ (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 151)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Aluminum hydroxide |
Approved, Investigational |
Phase 4 |
|
21645-51-2 |
|
Synonyms:
Al(OH)3
Aldrox
Algeldrate
Algeldrate atlas brand
Algeldrate axcan brand
Algeldrate chefaro brand
Algeldrate roques brand
Algeldrate stiefel brand
Algeldrate whitehall brand
Algeldrate wyeth brand
Alhydrogel
ALterna gel
Alugel
Alumina, hydrated
Aluminio hidróxido
Aluminium hydroxide
Aluminium hydroxide gel, dried
Aluminium hydroxide, dried
Aluminiumhydroxid
Aluminum hydroxide
Aluminum hydroxide gel, dried
Aluminum hydroxide, dried
Amphojel
|
Atlas brand OF algeldrate
Axcan brand OF algeldrate
Basalgel
Brasivil
chefaro Brand OF algeldrate
Dialume
Dried aluminium hydroxide
Dried aluminum hydroxide gel
Dried aluminum hydroxide gel fine granules
Hydrated alumina
Hydroxide, aluminum
Nephrox
Pepsamer
Rhône poulenc rorer brand OF algeldrate
Rhône-poulenc rorer brand OF algeldrate
Rocgel
Roques brand OF algeldrate
Sanofi winthrop brand OF algeldrate
SmithKline beecham brand OF algeldrate
Stiefel brand OF algeldrate
Whitehall brand OF algeldrate
Wyeth brand OF algeldrate
|
|
2 |
|
Racepinephrine |
Approved, Vet_approved |
Phase 4 |
|
51-43-4, 329-65-7 |
838 5816 |
Synonyms:
(−)-(R)-epinephrine
(-)-(R)-Epinephrine
(-)-3,4-Dihydroxy-a-((methylamino)methyl)benzyl alcohol
(-)-3,4-Dihydroxy-a-[(methylamino)methyl]-benzyl alcohol
(-)-3,4-Dihydroxy-a-[2-(methylamino)ethyl]benzyl alcohol
(-)-3,4-Dihydroxy-alpha-((methylamino)methyl)benzyl alcohol
(-)-3,4-Dihydroxy-alpha-[(methylamino)methyl]-benzyl alcohol
(-)-3,4-DIHYDROXY-ALPHA-[(METHYLAMINO)METHYL]BENZYL ALCOHOL(-)-3,4-DIHYDROXY-ALPHA-[(METHYLAMINO)METHYL]-BENZYL ALCOHOL
(-)-3,4-Dihydroxy-alpha-[2-(methylamino)ethyl]benzyl alcohol
(−)-3,4-dihydroxy-α-((methylamino)methyl)benzyl alcohol
(-)-3,4-Dihydroxy-α-((methylamino)methyl)benzyl alcohol
(-)-Adrenaline
(−)-ADRENALINE
(-)-Epinephrine
(+-)-Adrenaline
(+-)-Epinephrine
(R)-(-)-Adnephrine
(R)-(-)-Adrenaline
(R)-(−)-ADRENALINE
(R)-(-)-Epinephrine
(R)-(-)-Epirenamine
(R)-4-[1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
(R)-Adrenaline
(R)-Epinephrine
2-(Methylamino)-1-(3,4-dihydroxyphenyl)ethanol
4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-benzenediol
4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
4-[(1R)-1-HYDROXY-2-METHYLAMINOETHYL]BENZENE-1,2-DIOL
4-[(1R)-1-HYDROXY-2-METHYLAMINO-ETHYL]BENZENE-1,2-DIOL
4-[(1R)-1-HYDROXY-2-METHYLAMINO-ETHYL]PYROCATECHOL
Acetate, epinephrine
Adnephrine
ADREN CO
ADRENACLICK
Adrenal
Adrenalin
adrenalin|Auvi-Q®|Epipen®|l-adrenaline|L-epinephrine|levoepinephrine
Adrenaline
Adrénaline
Adrenaline acid tartrate
Adrenaline bitartrate
Adrenaline hydrochloride
Adrenaline hydrochloride, racemic mixture
Adrenaline, racemic
Adrenaline, racemic mixture
adrenaline|epinephrine
Adrenine
Adrin
Allergan brand OF adrenaline hydrochloride
ANA-GUARD
Ana-kit
ANAPEN
ANAPHYLACTIC SHOCK DRUG KIT
ASMA-VYDRIN
ASTHMAHALER
Auvi-Q
Bird brand OF racepinefrine hydrochloride
Bosmin
Bronkaid mist
BROVON
Chelafrin
DL-Adrenaline
EMERADE
EPI E Z PEN JR
Epifrin
Epiglaufrin
Epinefrin
Epinefrina
Epinephran
Epinephrin
EPINEPHRINE
Epinephrine acetate
Epinephrine bitartrate
EPINEPHRINE HCL
Epinephrine hydrochloride
Epinephrine hydrochloride, racemic mixture
Epinephrine hydrogen tartrate
Epinephrine racemic
Epinephrine, racemic
Epinephrine, racemic mixture
Epinephrinum
Epipen
|
EPIPEN E Z PEN
Epipen JR
EPIPEN JR.
Epirenan
Epitrate
Eppy
Exadrin
Glauposine
GPPE INH SOLN
Hemisine
Hemostasin
Hemostatin
Hydrochloride, racepinephrine
Hypernephrin
Isoptoepinal
JEXT
L-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
L-Adrenaline
L-DETHYLAMINOETHANOLCATECHOL
L-Epinephrine
L-Epirenamine
Levoepinephrine
LEVO-METHYLAMINOETHANOLCATECHOL
Levorenen
Levorenin
Levorenine
Levoreninum
L-Methylaminoethanolcatechol
Lyodrin
Lyophrin
Medihaler-epi
Methylarterenol
Micronefrin
Micronephrine
Mixture adrenaline, racemic
Mixture epinephrine, racemic
Mucidrina
Nephridine
Nieraline
NSC-62786
Paranephrin
Primatene
Primatene mist
R-(-)-Epinephrine
Racemic adrenaline
Racemic epinephrine
Racemic mixture adrenaline
Racemic mixture epinephrine
Racepinefrina
Racepinefrine
Racepinefrinum
Racepinephrine
Racepinephrine hydrochloride
Renaglandin
Renaleptine
Renalina
Renoform
Renostypticin
Renostyptin
RIDDOBRON
RIDDOFAN
RYBARVIN
Scurenaline
Simplene
SOLN MADE TO RYBARVIN FOR
Styptirenal
Supracapsulin
Supranephrane
Suprarenaline
Suprarenin
Surrenine
Sus-phrine
SUS-PHRINE SULFITE FREE
SUS-PHRINE SULFITE-FREE
SYMJEPI
Takamina
TWINJECT
TWINJECT 0.15
TWINJECT 0.3
Vaponefrin
Vasoconstrictine
Vasotonin
|
|
3 |
|
Bupivacaine |
Approved, Investigational |
Phase 4 |
|
2180-92-9, 38396-39-3 |
2474 |
Synonyms:
(+-)-Bupivacaine
(±)-bupivacaine
(RS)-bupivacaine
1-Butyl-2',6'-pipecoloxylidide
1-Butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide
Abbott brand OF bupivacaine hydrochloride
ANEKAIN
Anhydrous, bupivacaine
Astra brand OF bupivacaine hydrochloride
AstraZeneca brand OF bupivacaine hydrochloride
Aventis brand OF bupivacaine hydrochloride
Bloqueina
Braun brand OF bupivacaine hydrochloride
Braun, bupivacaina
Bucaine
Bupivacain janapharm
Bupivacain RPR
Bupivacaina
Bupivacaina [INN-Spanish]
Bupivacaina braun
BUPIVACAINE
Bupivacaine anhydrous
Bupivacaine carbonate
Bupivacaine HCL
Bupivacaine HCL kit
Bupivacaine hydrochloride
Bupivacaine monohydrochloride, monohydrate
Bupivacain-RPR
Bupivacainum
Bupivacainum [INN-Latin]
Bupivan
Buvacaina
|
Carbonate, bupivacaine
Carbostesin
CBupivacaine
Chirocaine
DepoBupivacaine
dl-1-Butyl-2',6'-pipecoloxylidide
DL-Bupivacaine
DL-Bupivacaine|Exparel®|Marcain®|Posimir®|Sensorcaine®|W-7|Xaracoll®
Dolanaest
DUR-843
Exparel
Hydrochloride, bupivacaine
Inibsa brand OF bupivacaine hydrochloride
Janapharm, bupivacain
Jenapharm brand OF bupivacaine hydrochloride
LAC-43
LIQ865
LIQ-865
Marcain
Marcaina
Marcaine
Marcaine HCL
Marcaine Spinal
Pisa brand OF bupivacaine hydrochloride
Racemic bupivacaine
Sensorcaine
Sensorcaine-MPF
Sensorcaine-MPF Spinal
SKY-0402
Strathmann brand OF bupivacaine hydrochloride
Svedocain sin vasoconstr
Transdur-Bupivacaine
|
|
4 |
|
Monophosphoryl lipid A |
|
Phase 4 |
|
|
|
5 |
|
Epinephryl borate |
|
Phase 4 |
|
|
|
6 |
|
Neurotransmitter Agents |
|
Phase 4 |
|
|
|
7 |
|
Bronchodilator Agents |
|
Phase 4 |
|
|
|
8 |
|
Adrenergic beta-Agonists |
|
Phase 4 |
|
|
|
9 |
|
Adrenergic alpha-Agonists |
|
Phase 4 |
|
|
|
10 |
|
Adrenergic Agonists |
|
Phase 4 |
|
|
|
11 |
|
Anti-Asthmatic Agents |
|
Phase 4 |
|
|
|
12 |
|
Adrenergic Agents |
|
Phase 4 |
|
|
|
13 |
|
Vasoconstrictor Agents |
|
Phase 4 |
|
|
|
14 |
|
Anesthetics, Local |
|
Phase 4 |
|
|
|
15 |
|
Respiratory System Agents |
|
Phase 4 |
|
|
|
16 |
|
Mydriatics |
|
Phase 4 |
|
|
|
17 |
|
Sympathomimetics |
|
Phase 4 |
|
|
|
18 |
|
Vaccines |
|
Phase 4 |
|
|
|
19 |
|
Fluorouracil |
Approved |
Phase 3 |
|
51-21-8 |
3385 |
Synonyms:
5 Fluorouracil
5 Fluorouracil biosyn
5 FU
5 FU lederle
5 FU medac
5 HU hexal
5.F.U.
5-Fluoracil
5-Fluoropyrimidine-2,4-dione
5-Fluorouracil
5-Fluorouracil-biosyn
5-Fluracil
5FU
5-FU
5-FU lederle
5-FU medac
5-HU hexal
ACCUSITE
ACTIKERALL
Adrucil
Allergan brand OF fluorouracil
Arumel
Biosyn brand OF fluorouracil
Carac
Carzonal
CSP Brand OF fluorouracil
Dakota brand OF fluorouracil
Dakota, fluorouracile
Dermatech brand OF fluorouracil
Dermik brand OF fluorouracil
Effluderm
Efudex
Efudix
Efurix
Ferrer brand OF fluorouracil
Fluoro Uracil
Fluoro uracile icn
Fluoroblastin
Fluoroplex
Fluorouracil
Fluorouracil gry
Fluorouracil mononitrate
Fluorouracil monopotassium salt
Fluorouracil monosodium salt
Fluorouracil potassium salt
FLUORO-URACIL ROCHE
Fluorouracil teva brand
|
Fluorouracile dakota
Fluoro-uracile icn
Fluorouracil-gry
Fluorouracilo
Fluorouracilo ferrer far
Fluorouracilum
Fluoruracil
Fluouracil
Fluracedyl
FLURACIL
Fluracilum
Fluri
Fluril
Fluro Uracil
Flurodex
Flurouracil
Ftoruracil
FU
Gry brand OF fluorouracil
Haemato brand OF fluorouracil
Haemato fu
Haemato-fu
Hexal brand OF fluorouracil
ICN brand OF fluorouracil
Kecimeton
Medac brand OF fluorouracil
Neocorp brand OF fluorouracil
Neofluor
NSC-19893
Onkofluor
Onkoworks brand OF fluorouracil
Pharmachemie brand OF fluorouracil monosodium salt
Phthoruracil
Phtoruracil
Queroplex
Ribofluor
Ribosepharm brand OF fluorouracil
Riemser brand OF fluorouracil
RO-29757
RO-2-9757
Roche brand OF fluorouracil
Teva brand OF fluorouracil
Timazin
TOLAK
Ulup
URF
|
|
20 |
|
Aluminum sulfate |
Approved |
Phase 3 |
|
10043-01-3 |
|
Synonyms:
Aluminium sulfate
Aluminium sulfate anhydrous
Aluminum sulfate anhydrous
|
Aluminum sulphate anhydrous
Dialuminum sulfate
Dialuminum trisulfate
|
|
21 |
|
Lidocaine |
Approved, Vet_approved |
Phase 3 |
|
137-58-6 |
3676 |
Synonyms:
2-(Diethylamino)-2',6'-acetoxylidide
2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide
2-2ETN-2MePhAcN
a-Diethylamino-2,6-dimethylacetanilide
ALGRX 3268
ALGRX-3268
ALPHACAINE
alpha-Diethylamino-2,6-dimethylacetanilide
ANESTACON
Astrazeneca brand OF lidocaine
Dalcaine
Dentipatch
Dilocaine
EMBOLEX
IONTOCAINE
Jenapharm brand OF lidocanine hydrochloride
L-Caine
Lidocaina
Lidocaína
LIDOCAINE
Lidocaine carbonate
Lidocaine carbonate (2:1)
Lidocaine hydrocarbonate
Lidocaine hydrochloride
Lidocaine monoacetate
Lidocaine monohydrochloride
|
Lidocaine monohydrochloride, monohydrate
Lidocaine sulfate (1:1)
Lidocainum
LIDOCATON
Lidoderm
LIDOPEN
Lignocaine
LIGNOCAINE HCL
LIGNOSTAB
LMX 4
Novocol brand OF lidocaine hydrochloride
NSC-40030
Octocaine
ORAQIX
Strathmann brand OF lidocaine hydrochloride
VAGISIL
Xylesthesin
Xylocaine
Xylocaine®
Xylocitin
XYLODASE
Xyloneural
XYLOTOX
ZTLIDO
Α-diethylamino-2,6-dimethylacetanilide
|
|
22 |
|
Eugenol |
Approved |
Phase 3 |
|
97-53-0 |
3314 |
Synonyms:
1,3,4-EUGENOL
1-ALLYL-3-METHOXY-4-HYDROXYBENZENE
1-ALLYL-4-HYDROXY-3-METHOXYBENZENE
1-HYDROXY-2-METHOXY-4-ALLYLBENZENE
1-HYDROXY-2-METHOXY-4-PROP-2-ENYLBENZENE
1-HYDROXY-2-METHOXY-4-PROPENYLBENZENE
2-HYDROXY-5-ALLYLANISOLE
2-METHOXY-1-HYDROXY-4-ALLYLBENZENE
2-Methoxy-4-(2’-propenyl)phenol
2-METHOXY-4-(2-PROPEN-1-YL)PHENOL
2-Methoxy-4-(2'-propenyl)phenol
2-METHOXY-4-(2-PROPENYL)PHENOL
2-METHOXY-4-(3-PROPENYL)PHENOL
2-METHOXY-4-(PROP-2-EN-1-YL)PHENOL
2-Methoxy-4-[2-allyl]phenol
2-METHOXY-4-ALLYLPHENOL
2-Methoxy-4-prop-2-enyl-phenol
2-METHOXY-4-PROP-2-ENYLPHENOL
3-(3-Methoxy-4-hydroxyphenyl)propene
3-(4-Hydroxy-3-methoxyphenyl)-1-propene
4-Allenylguaiacol
|
4-ALLYL-1-HYDROXY-2-METHOXYBENZENE
4-ALLYL-2-METHOXYPHENOL
4-ALLYL-2-METHOXY-PHENOL
4-ALLYLCATECHOL 2-METHYL ETHER
4-ALLYLCATECHOL-2-METHYL ETHER
4-ALLYLGUAIACOL
4-HYDROXY-3-METHOXY-1-ALLYLBENZENE
4-HYDROXY-3-METHOXYALLYLBENZENE
5-Allylguaiacol
ALLYLGUAIACOL
Caryophyllate
CARYOPHYLLIC ACID
ENGENOL
Eugenate
EUGENIC ACID
EUGENOL
Eugenol (natural)
P-ALLYLGUAIACOL
P-EUGENOL
Synthetic eugenol
|
|
23 |
|
Imiquimod |
Approved, Investigational |
Phase 3 |
|
99011-02-6 |
57469 |
Synonyms:
1-Isobutyl-1H-imidazo(4,5-c)quinolin-4-amine
1-Isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
4-Amino-1-isobutyl-1H-imidazo(4,5-c)quinoline
Aldara
Aldara®|R837|S-26308|Zyclara®
Imiquimod
Imiquimod acetate
|
Imiquimodum
R 837
R-837
S-26308
ZARTRA
Zyclara
|
|
24 |
|
Acetic acid |
Approved |
Phase 3 |
|
64-19-7 |
176 |
Synonyms:
Acetasol
Acetate
acetate|ethanoic acid
Acetic acid
Acetic acid glacial
Acetic acid, glacial
Aceticum acidum
Acid glacial, acetic
Acid, acetic
Acid, glacial acetic
Acide acetique
acide acétique
ácido acético
AcOH
CH3CO2H
CH3-COOH
e 260
e260
e-260
Essigsaeure
|
Essigsäure
Ethanoat
Ethanoate
Ethanoic acid
Ethoate
Ethoic acid
Ethylate
Ethylic acid
Glacial acetate
Glacial acetic acid
Glacial, acetic acid
HOAc
INS no. 260
Kyselina octova
MeCO2h
MeCOOH
Methanecarboxylate
Methanecarboxylic acid
Vinegar
Vinegar acid
|
|
25 |
|
Fenretinide |
Investigational |
Phase 3 |
|
65646-68-6 |
5288209 |
Synonyms:
4-HPR
4-hydroxy(phenyl)retinamide
4-hydroxyphenyl retinamide
ALL-TRANS-4'-HYDROXYRETINANILIDE
Fenretinida
|
Fenretinide
Fenretinidum
MCN-R-1967
N-(4-hydroxyphenyl)all-trans retinamide
N-(4-HYDROXYPHENYL)RETINAMIDE
|
|
26 |
|
3,3'-diindolylmethane |
Investigational |
Phase 3 |
|
1968-05-4 |
3071 |
Synonyms:
1,1-BIS(3'-INDOLYL)METHANE
2,2'-Methylenebis(1H-indole)
3,3'-DIINDOLYLMETHANE
3,3-DIINDOLYLMETHANE
3,3'-Methylenebis-1H-indole
|
ARUNDINE
Bis-1H-indol-3-ylmethane
Diindolylmethane
DIM
|
|
27 |
|
Zuretinol acetate |
Investigational |
Phase 3 |
|
127-47-9, 29584-22-3 |
10245972 |
Synonyms:
(2E,4E,6Z)-3,7-Dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraen-1-yl acetic acid
13-cis-Retinyl acetate
9-cis-Retinyl acetate
Acetateall-trans-retinol
Acetic acid, retinyl ester
all-trans-Retinol acetate
all-trans-Retinyl acetate
all-trans-Retinylacetate
all-trans-Vitamin a acetate
Crystalets
Dagravit a forte
Davitan a 650
Dif vitamin a masivo
Myvak
Myvax
O(15)-Acetylretinol
O~15~-acetylretinol
O~15~-acetyl-retinol
RetiNit
Retinol acetate
|
Retinol acetate (JP15)
RETINOL acetATE (see retinoidprojects 1 and 3)
Retinol acetate, (9,13-cis)-isomer
Retinol acetic acid
Retinol, acetate
Retinol, acetate, all-trans- (8ci)
Retinol, acetate, labeled with tritium
Retinyl acetate
trans-Retinyl acetate
trans-Vitamin a acetate
Vitamin a acetate
Vitamin a acetate (tritiated)
Vitamin a alcohol acetate
Vitamin a dispersa
Vitamin a ester
Vitamin a, acetate
Vitamin a1 acetate
Vitamin-a-saar
Zuretinol acetate
Zuretinol acetic acid
|
|
28 |
|
Antimetabolites |
|
Phase 3 |
|
|
|
29 |
|
Immunosuppressive Agents |
|
Phase 3 |
|
|
|
30 |
|
Anesthetics |
|
Phase 3 |
|
|
|
31 |
|
Antiviral Agents |
|
Phase 3 |
|
|
|
32 |
|
Retinamide |
|
Phase 3 |
|
|
|
33 |
|
Protective Agents |
|
Phase 3 |
|
|
|
34 |
|
Immunoglobulins |
|
Phase 3 |
|
|
|
35 |
|
Antibodies |
|
Phase 3 |
|
|
|
36 |
|
Hemostatics |
|
Phase 3 |
|
|
|
37 |
|
Olive |
|
Phase 3 |
|
|
|
38 |
|
Anti-Arrhythmia Agents |
|
Phase 3 |
|
|
|
39 |
|
Sodium Channel Blockers |
|
Phase 3 |
|
|
|
40 |
|
Diuretics, Potassium Sparing |
|
Phase 3 |
|
|
|
41 |
|
Adjuvants, Immunologic |
|
Phase 3 |
|
|
|
42 |
|
interferons |
|
Phase 3 |
|
|
|
43 |
|
Immunologic Factors |
|
Phase 3 |
|
|
|
44 |
|
Raspberry |
Approved |
Phase 2 |
|
|
|
45 |
|
Aluminium phosphate |
Approved, Investigational |
Phase 2 |
|
7784-30-7 |
|
Synonyms:
ALUMINIUM PHOSPHATE
ALUMINIUM PHOSPHATE GEL
|
ALUMINUM PHOSPHATE
PHOSPHALJEL
|
|
46 |
|
Eflornithine |
Approved, Withdrawn |
Phase 2 |
|
70052-12-9 |
3009 |
Synonyms:
(RS)-2,5-diamino-2-(difluoromethyl)pentanoic acid
2-(difluoromethyl)ornithine
2-(difluoromethyl)ornithine (DMFO)|difluoromethylornithine|Ornidyl®|Vaniqa®
a-(Difluoromethyl)-DL-ornithine
a-Difluoromethylornithine
alpha Difluoromethyl ornithine
alpha Difluoromethylornithine
alpha-(Difluoromethyl)-DL-ornithine
alpha-Difluoromethyl ornithine
alpha-Difluoromethylornithine
DFMO
Difluoromethylornithine
DL alpha Difluoromethylornithine
DL-alpha-Difluoromethylornithine
|
Eflornithine
Eflornithine hydrochloride
Eflornithine monohydrochloride, monohydrate
Hydrochloride, eflornithine
MDL 71,782 a
MDL71,782 a
MDL-71,782 a
Monohydrochloride, monohydrate eflornithine
Ornidyl
Ornithine, alpha-difluoromethyl
Vaniqa
Women first brand OF eflornithine hydrochloride
Α-(difluoromethyl)-DL-ornithine
Α-difluoromethylornithine
|
|
47 |
|
Celecoxib |
Approved, Investigational |
Phase 2 |
|
169590-42-5 |
2662 |
Synonyms:
4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide
4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENE-1-SULFONAMIDE
4-[5-(4-METHYLPHENYL)-3-TRIFLUOROMETHYL)-1H-PYRAZOL-YL]BENZENESULFONAMIDE
CELEBRA
Celebrex
CELECOX
Celecox®|Elyxyb® (DFN-15; oral solution)|Onsenal®|SC-58635|SC58635
Celecoxib
Célécoxib
|
Celecoxibum
Celocoxib
DFN15
DFN-15
Onsenal
p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulphonamide
SC-58635
|
|
48 |
|
Masoprocol |
Approved, Investigational |
Phase 1, Phase 2 |
|
500-38-9, 27686-84-6 |
71398 |
Synonyms:
(R*,s*)-4,4'-(2,3-dimethylbutane-1,4-diyl)bispyrocatechol
Acid, meso-nordihydroguaiaretic
Actinex
CHX 100
CHX-100
Dihydronorguaiaretic acid
Erythro-nordihydroguaiaretate
Erythro-nordihydroguaiaretic acid
INSM-18
Masoprocol
Masoprocolum
Meso nordihydroguaiaretic acid
Meso-1,4-bis(3,4-dihydroxyphenyl)-2,3-dimethylbutane
Meso-2,3-bis(3,4-dihydroxyphenylmethyl)butane
Meso-4,4'-(2,3-dimethyl-1,4-butanediyl)bis(pyrocatechol)
Meso-4,4'-(2,3-dimethyltetramethylene)dipyrocatechol
|
Meso-4-[4-(3,4-dihydroxyphenyl)-2,3-dimethylbutyl]benzene-1,2-diol
Meso-b,g-dimethyl-a,delta-bis(3,4-dihydroxyphenyl)butan
Meso-b,g-dimethyl-a,δ-bis(3,4-dihydroxyphenyl)butan
Meso-beta,gamma-dimethyl-alpha,delta-bis(3,4-dihydroxyphenyl)butan
Meso-ndga
Meso-nordihydroguaiaretate
Meso-nordihydroguaiaretic acid
Meso-β,γ-dimethyl-α,δ-bis(3,4-dihydroxyphenyl)butan
NDGA
Nordihydroguaiaretate
Nordihydroguaiaretic acid
Nordihydroguaiaretic acid, (r*,s*)-isomer
Nordihydroguairaretic acid
NSC-4291
NSC-682984
|
|
49 |
|
Levoleucovorin |
Approved, Experimental, Investigational |
Phase 2 |
|
68538-85-2, 58-05-9, 73951-54-9 |
149436 6006 |
Synonyms:
(5-formyl-5,6,7,8-tetrahydropteroyl)glutamate
(6R)-Leucovorin
(6R,2'S)-Folinic acid
(6R,S)-5-Formyltetrahydrofolate
(6S)-5-Formyl-5,6,7,8-tetrahydrofolate
(6S)-5-FORMYL-5,6,7,8-TETRAHYDROFOLIC ACID
(6S)-5-Formyltetrahydrofolate
(6S)-5-FORMYLTETRAHYDROFOLIC ACID
(6S)-Folinate
(6S)-FOLINIC ACID
(6S)-LEUCOVORIN
(S)-LEUCOVORIN
[6R]-5-formyl-5,6,7,8-tetrahydrofolate
10-Formyl-7,8-dihydrofolate
10-Formyl-7,8-dihydrofolic acid
5 Formyltetrahydrofolate
5 Formyltetrahydropteroylglutamate
5-Formlyl-5,6,7,8-tetrahydrofolate,calcium salt
5-Formyl-(6S)-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydrofolate
5-Formyl-5,6,7,8-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic acid
5-Formyltetrahydrofolate
5-Formyltetrahydrofolic acid
5-Formyltetrahydropteroylglutamate
5-Formyltetrahydropteroylglutamic acid
5-formylTHF
6 S Leucovorin
6R-Leucovorin
6S Leucovorin
6S-Leucovorin
6-S-Leucovorin
Acid, folinic
Acide folinique
Acido folinico
ácido levofolínico
Calcium citrovorum factor
Calcium folinate
Calcium leucovorin
CF
Citrovorum factor
Dextrofolinic acid
Factor, citrovorum
Folinate
Folinate, calcium
Folinic acid
Folinic acid calcium salt
Folinic acid calcium salt USP27
Folinic acid SF
Folinic acid-SF
FUSILEV
KHAPZORY
|
Kunyrin
L(-)-5-Formyl-5,6,7,8-tetrahydrofolate
L(-)-5-Formyl-5,6,7,8-tetrahydrofolic acid
Leucal
Leucoverin
Leucovorin
Leucovorin calcium
Leucovorin folinic acid
Leucovorin, (D)-isomer
Leucovorin, (DL)-isomer
Leucovorin, (R)-isomer
Leucovorin, (S)-isomer
Leucovorin, calcium
Leucovorin, calcium (1:1) salt
Leucovorin, calcium (1:1) salt, (DL)-isomer
Leucovorin, calcium (1:1) salt, (S)-isomer
Leucovorin, calcium (1:1) salt, pentahydrate
Leucovorin, monopotassium salt, (S)-isomer
Leucovorin, monosodium salt
Leucovorin, monosodium salt, (S)-isomer
Leucovorinum
Leukovorin
Leukovorum
Levo leucovorin
LEVOFOLENE
Levofolinate
LEVOFOLINIC ACID
Levoleucovorin
Levo-leucovorin
L-Folinate
L-FOLINIC ACID
LFP-754
L-Leucovorin
L-N-[P-[[(2-amino-5-Formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl]amino]benzoyl]-glutamic acid
Monosodium salt leucovorin
N(5)-Formyltetrahydrofolate
N-(5-formyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid
N-[4-({[(6S)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamate
N-[4-({[(6S)-2-AMINO-5-FORMYL-4-OXO-1,4,5,6,7,8-HEXAHYDROPTERIDIN-6-YL]METHYL}AMINO)BENZOYL]-L-GLUTAMIC ACID
N-{[4-({[(6R)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)phenyl]carbonyl}-L-glutamic acid
N5-Formyl-5,6,7,8-tetrahydrofolate
N5-Formyl-5,6,7,8-tetrahydrofolic acid
N5-Formyltetrahydrofolate
N5-Formyltetrahydrofolic acid
N5-Formyl-THF
Pteroyl-D-glutamate
Rescuvolin
S Leucovorin
S-Leucovorin
Welcovorin
Wellcovorin
|
|
50 |
|
Pemetrexed |
Approved, Investigational |
Phase 2 |
|
150399-23-8, 137281-23-3 |
60843 446556 135565230 |
Synonyms:
(2R)-2-{[4-(2-{4-hydroxy-2-imino-1H,2H,7H-pyrrolo[2,3-D]pyrimidin-5-yl}ethyl)phenyl]formamido}pentanedioate
ALIMTA
Alimta®|LY-231514
Disodium, pemetrexed
LY-2315
LY231514
|
LY-231514
MTA
N-(4-(2-(2-Amino-3,4-dihydro-4-oxo-7H-pyrrolo(2,3-D)pyrimdin-5-yl)ethyl)benzoyl)glutamic acid
NSC-698037
Pemetrexed
Pemetrexed disodium
|
|
Interventional clinical trials:
(show top 50)
(show all 302)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
A Randomized Controlled Trial Evaluating the Efficacy of Tachosil® for Prevention of Hemorrhage After Loop Electrosurgical Excisional Procedure (LEEP) in Patients With Cervical Intraepithelial Neoplasia or Cervical Cancer |
Unknown status |
NCT02629510 |
Phase 4 |
Tachosil |
2 |
Can Mindfulness Meditation Limit the Progression and/or Increase the Remission of Cervical Dysplasia? |
Unknown status |
NCT00842738 |
Phase 4 |
|
3 |
Management of Cervical Intraepithelial Neoplasia Grade 2 |
Completed |
NCT00733109 |
Phase 4 |
|
4 |
HPV Vaccination Impact on Cervical Cancer Screening Program: FASTER-Tlalpan Study in Mexico |
Completed |
NCT03105856 |
Phase 4 |
|
5 |
Hemodynamic Stability of Bupivacaine With and Without Adrenaline for Paracervical Block for Cervical Conization During General Anesthesia: A Randomized Controlled Double Blinded Study |
Completed |
NCT02368054 |
Phase 4 |
Bupivacaine;Adrenaline |
6 |
Safety and Protective Effect Study of GSK Biologicals' Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed (GSK580299) in Healthy Female Subjects From the HPV-039 Study |
Completed |
NCT03629886 |
Phase 4 |
|
7 |
A Phase IV Open-Label, Descriptive Study to Evaluate the Safety and Effectiveness on the Incidence of HPV 6, 11, 16 and 18 Related CIN 2/3 or Worse of the Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in 16- to 26-Year-Old Japanese Women |
Completed |
NCT01544478 |
Phase 4 |
|
8 |
A Study to Assess the Immunogenicity Consistency of Three Consecutive Batches of Commercial-scale of Recombinant Human Papillomavirus(HPV) Bivalent Vaccine (Escherichia Coli) in Healthy Female Subjects Aged 9-14 Years |
Completed |
NCT05426148 |
Phase 4 |
|
9 |
Comparison of Immune Response to the Human Papillomavirus Vaccine in Young Women With and Without Inflammatory Bowel Disease |
Completed |
NCT01034358 |
Phase 4 |
|
10 |
Effectiveness of Cervical Screening in HPV Vaccinated Women - A Randomized Trial |
Active, not recruiting |
NCT02149030 |
Phase 4 |
|
11 |
Prospective Observational Immunogenicity Trial of Gardasil-9 HPV Vaccine in People Living With Adequately Managed HIV |
Not yet recruiting |
NCT05266898 |
Phase 4 |
|
12 |
A Randomized, Single Blinded Trial to Evaluate the Efficacy of Imiquimod in Women With Residual/Recurrent Cervical Intraepithelial Neoplasia (CIN) After Previous Treatment |
Unknown status |
NCT02669459 |
Phase 3 |
Imiquimod |
13 |
DNA Methylation Testing for the Screening of Uterine Cervical Lesion: A Multicenter, Prospective Cohort Study |
Unknown status |
NCT04646954 |
Phase 3 |
|
14 |
A Phase III Double Blinded, Randomized Controlled Study to Evaluate Efficacy of Protection Against HPV-16 and 18 Related Diseases, Immunogenicity and Safety of HPV-16/18 Vaccine in Healthy Females Aged 18-30 Years |
Unknown status |
NCT02733068 |
Phase 3 |
|
15 |
The Study of Folate Receptor-Mediated Staining Solution (FRD™) In Cervical |
Unknown status |
NCT03366493 |
Phase 3 |
|
16 |
Randomized Controlled Trial of Vaginal Self Sampling for Human Papillomavirus to Increase Cervical Cancer Screening Participation |
Unknown status |
NCT01095198 |
Phase 2, Phase 3 |
|
17 |
A Double-Blind, Controlled, Randomized, Phase III Study of the Efficacy of an HPV16/18 VLP Vaccine in the Prevention of Advanced Cervical Intraepithelial Neoplasia (CIN2, CIN3, Adenocarcinoma In Situ [AIS] and Invasive Cervical Cancer) Associated With HPV 16 or HPV 18 Cervical Infection in Healthy Young Adult Women in Costa Rica. |
Completed |
NCT00128661 |
Phase 3 |
|
18 |
A Randomized Double-Blind Study of N-(4-hydroxyphenyl) Retinamide (4-HPR) Versus Placebo in Patients With Cervical Intraepithelial Neoplasia (CIN) Grade 2-3 |
Completed |
NCT00003075 |
Phase 3 |
Fenretinide |
19 |
Topical Imiquimod in Treating Patients With Grade 2/3 Cervical Intraepithelial Neoplasia |
Completed |
NCT00941252 |
Phase 2, Phase 3 |
Topical imiquimod therapy |
20 |
Long-term Extension Study of the Efficacy of the 580299 Vaccine in the Prevention of HPV-16 and/or HPV-18 Associated Cervical Intraepithelial Neoplasia (CIN) in Japanese Women Vaccinated in the Primary Vaccination Study NCT00316693 |
Completed |
NCT00929526 |
Phase 3 |
|
21 |
Diindolylmethane (DIM) Dietary Supplementation: A Nonsurgical Treatment for Cervical Intraepithelial Neoplasia (CIN) |
Completed |
NCT00212381 |
Phase 3 |
di indolylmethane (DIM) |
22 |
Immunogenicity and Safety Study of a Bivalent Human Papillomavirus (Type 16, 18) Recombinant Vaccine (E.Coli) in Healthy Female Subjects Aged 9 to 17 Years |
Completed |
NCT02562508 |
Phase 3 |
|
23 |
Large Loop Excision of Transformation Zone Cone Versus Straight Wire Excision of Transformation Zone : Histopathological Analysis of Excision Margins |
Completed |
NCT01929993 |
Phase 3 |
|
24 |
Phase 3 Randomized Controlled Trial of Non-inferiority of Topical Imiquimod vs. LEEP for Women With Carcinoma In-situ of the Cervix |
Completed |
NCT02130323 |
Phase 2, Phase 3 |
Imiquimod |
25 |
Persistence of Immune Response to GSK Biologicals' HPV Vaccine in Healthy Chinese Female Subjects From the HPV-058 Study |
Completed |
NCT03355820 |
Phase 3 |
|
26 |
Randomized Trial of Immediate Treatment vs. Colposcopic Follow-up for Biopsy-Proven CIN 1 |
Completed |
NCT00156026 |
Phase 3 |
|
27 |
A Study of Two Cone Biopsy Techniques For Women With Cervical Pre-Invasive Disease. LLETZ Cone and SWETZ. |
Completed |
NCT00995020 |
Phase 3 |
|
28 |
Randomized Clinical Trial on Clinical Management of ASCUS and LSIL (ALTS) |
Completed |
NCT01131312 |
Phase 3 |
|
29 |
A Long-term, Open, Follow-up of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV-16/18 L1/AS04 Vaccine in Healthy Female Subjects Vaccinated Either Pre- or Post-menarche in the Primary Study |
Completed |
NCT00337818 |
Phase 3 |
|
30 |
A Long-term, Open Follow-up of the Immunogenicity and Safety of GSK Biologicals' HPV Vaccine (580299) in Healthy Female Subjects Vaccinated in Study HPV-013 |
Completed |
NCT00316706 |
Phase 3 |
|
31 |
Single Visit Cervical Cancer Prevention Program |
Completed |
NCT00237562 |
Phase 3 |
|
32 |
A Phase III Multicenter, Randomized, Double-Blind, Placebo(Hepatitis E Vaccine)Controlled Study to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant(E.Coli)Human Papillomavirus Bivalent Vaccine in Healthy Women |
Completed |
NCT01735006 |
Phase 3 |
|
33 |
Randomized Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL |
Completed |
NCT03721978 |
Phase 3 |
|
34 |
Human Papillomavirus DNA Testing Using Self-collected Samples for Cervical Cancer Screening: an Alternative Strategy for Unscreened Women? |
Completed |
NCT01014026 |
Phase 3 |
|
35 |
Efficiency of AV2 Antiviral Drug in the Treatment of Human Papillomavirus-associated Precancerous Lesions of the Uterine Cervix: a Randomized Clinical Trial in Kinshasa, Democratic Republic of the Congo |
Completed |
NCT02346227 |
Phase 3 |
AV2;Placebo |
36 |
A Phase III Randomized Trial of Topical Vaginal Fluorouracil (5-Fluorouracil, 5-FU) Maintenance Therapy Versus Observation After Standard Treatment for High-Grade Cervical Dysplasia in HIV-Infected Women |
Completed |
NCT00000758 |
Phase 3 |
Fluorouracil |
37 |
A Prospective, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation With CELLECTRA™-5PSP for the Treatment of HPV-16 and/or HPV-18 Related High Grade Squamous Intraepithelial Lesion (HSIL) of the Cervix |
Completed |
NCT03185013 |
Phase 3 |
|
38 |
A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of Amolimogene (ZYC101a) in the Treatment of High-Grade Cervical Intraepithelial Lesions (CIN 2/3) of the Uterine Cervix |
Completed |
NCT00264732 |
Phase 2, Phase 3 |
Amolimogene |
39 |
Forced Versus Spray Coagulation in Women Undergoing LLETZ-conization for Cervical Dysplasia: a Randomized Trial |
Completed |
NCT02330471 |
Phase 3 |
|
40 |
Lidocaine Spray Compared With Submucosal Injection in Reducing Pain During Loop Electrosurgical Excision Procedure: a Randomized Controlled Trial |
Completed |
NCT01505920 |
Phase 3 |
|
41 |
A Double Blind, Prospective, Randomized, Placebo Controlled, Multi-center Phase 3 Study to Evaluate Efficacy and Safety of Cevira® in Patients With Cervical Histologic High-grade Squamous Intraepithelial Lesions (HSIL) |
Active, not recruiting |
NCT04484415 |
Phase 3 |
|
42 |
A Multicenter, Randomized, Double-Blind, Controlled (Bivalent Human Papillomavirus Vaccine (16,18 Type)(E. Coli)) Phase III Clinical Trial to Estimate Efficacy, Immunogenicity and Safty of the Recombinant Human Papillomavirus Vaccine (6,11,16,18,31,33,45,52,58 Type) (E.Coli) in Healthy Women Aged 18 to 45 Years |
Active, not recruiting |
NCT04537156 |
Phase 3 |
|
43 |
A Phase 3 Open-Label Clinical Trial to Study the Immunogenicity, Safety and Tolerability of Recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years |
Active, not recruiting |
NCT03493542 |
Phase 3 |
|
44 |
A Randomised, Double-Blind, Placebo-Controlled, Phase III Study to Investigate the Efficacy of Presurgical 9-valent HPV Vaccination in Women Treated With LEEP for CIN 2+ and Initially Invasive Cervical Cancer. |
Not yet recruiting |
NCT03848039 |
Phase 3 |
Placebo |
45 |
A Randomized Trial of Spectroscopy Versus Standard Care in Cervical Intraepithelial Neoplasia |
Terminated |
NCT00529464 |
Phase 3 |
|
46 |
ITIC2 Trial - Topical Imiquimod Versus Conization to Treat Cervical Intraepithelial Neoplasia: Randomised Controlled, Non-inferiority Trial |
Terminated |
NCT01283763 |
Phase 3 |
Topical Imiquimod |
47 |
TOPical Imiquimod Treatment of High-grade Cervical Intraepithelial Neoplasm: a Randomized Controlled Trial. |
Terminated |
NCT02329171 |
Phase 3 |
Imiquimod |
48 |
A Phase 2 Trial to Evaluate the Efficacy and the Safety of Composite Gel Containing Black Raspberry Extract in Removing HPV From Patients With Cervical Intraepithelial Neoplasia(CIN) After Cervical Conization |
Unknown status |
NCT03745846 |
Phase 2 |
|
49 |
A Phase 2b Trial to Evaluate the Efficacy and Safety of BLS-ILB-E710c in Patients With Cervical Intraepithelial Neoplasia 2/3 (CIN2/3) |
Unknown status |
NCT03274206 |
Phase 2 |
Placebo |
50 |
A Randomized, Double-blind, Placebo-controlled, Multi-center, Phase 2 Clinical Trial to Evaluate the Efficacy and the Safety of GX-188E, a DNA-based Therapeutic Vaccine, Administered Intramuscularly by Electroporation(EP) in HPV Type 16 and/or 18 Positive Patients With Biopsy-proven Cervical Intraepithelial Neoplasia Grade 2(CIN2), Grade 2/3 (CIN2/3), Grade 3(CIN3) |
Unknown status |
NCT02596243 |
Phase 2 |
|
|